| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/19/2013 | US20130245004 Acamprosate formulations, methods of using the same, and combinations comprising the same |
| 09/19/2013 | US20130245002 Triazolopyridine Compounds |
| 09/19/2013 | US20130245000 Bicyclic gpr119 modulators |
| 09/19/2013 | US20130244999 Substituted Heterocyclic Compounds |
| 09/19/2013 | US20130244988 Carbonate and carbamate modified forms of glucocorticoids in combination with b2 adrenergic agonists |
| 09/19/2013 | US20130244986 Methods of treating skin disorders with caffeic acid analogs |
| 09/19/2013 | US20130244974 Surgical hydrogel |
| 09/19/2013 | US20130244971 Stabilized ophthalmic galactomannan formulations |
| 09/19/2013 | US20130244963 Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide |
| 09/19/2013 | US20130244962 Cysteine protease inhibitors for the treatment of parasitic diseases |
| 09/19/2013 | US20130244951 Treatment of solid tumors with rapamycin derivatives |
| 09/19/2013 | US20130244941 Use Of C1 Inhibitor For The Prevention Of Ischemia-Reperfusion Injury |
| 09/19/2013 | US20130244934 Vip fragments and methods of use |
| 09/19/2013 | US20130244927 Polynucleotides encoding signal peptide-containing molecules |
| 09/19/2013 | US20130244924 Peptide compounds to regulate the complement system |
| 09/19/2013 | US20130243886 Novel use |
| 09/19/2013 | US20130243876 Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells |
| 09/19/2013 | US20130243842 Compositions and methods for treating bone diseases and broken bones |
| 09/19/2013 | US20130243796 Genetic products differentially expressed in tumors and use thereof |
| 09/19/2013 | US20130243794 Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses |
| 09/19/2013 | US20130243786 Treatment of juvenile rheumatoid arthritis (jra) |
| 09/19/2013 | US20130243780 Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof |
| 09/19/2013 | US20130243774 Notch1 binding agents and methods of use thereof |
| 09/19/2013 | US20130243758 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| 09/19/2013 | US20130243756 Methods for Treating Diseases and HSV Using Antibodies to Aminophospholipids |
| 09/19/2013 | US20130243754 Heterocyclic compounds and methods of use |
| 09/19/2013 | US20130243753 Anti-axl antibodies and methods of use |
| 09/19/2013 | US20130243750 Anti-ige antibodies and methods using same |
| 09/19/2013 | US20130243743 Methods and compositions for treating ineffective erythropoiesis |
| 09/19/2013 | US20130243737 Calcium-containing structures and methods of making and using the same |
| 09/19/2013 | US20130243734 Methods and compositions for wound healing |
| 09/19/2013 | US20130243733 Compositions and methods for regulating angiogenesis |
| 09/19/2013 | US20130243731 Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies |
| 09/19/2013 | US20130243727 Triazoles as inhibitors of fatty acid synthase |
| 09/19/2013 | US20130243725 2'-substituted carba-nucleoside analogs for antiviral treatment |
| 09/19/2013 | US20130243723 Vaccine immunotherapy |
| 09/19/2013 | US20130243720 Iron(II)-Containing A Treatments for Hyperphosphatemia |
| 09/19/2013 | US20130243707 Topical compositions |
| 09/19/2013 | US20130243696 Compositions and Methods for the Treatment of Traumatic Brain Injury |
| 09/18/2013 | EP2638917A1 Method of fixing and expressing physiologically active substance |
| 09/18/2013 | EP2638910A2 Composition comprising benproperine derivatives as active ingredients for preventing and treating angiogenesis-related diseases |
| 09/18/2013 | EP2638038A1 Method of treatment for mental disorders |
| 09/18/2013 | EP2637695A1 Olmesartan formulations |
| 09/18/2013 | EP2637694A1 Conjugates of an il-2 moiety and a polymer |
| 09/18/2013 | EP2637663A1 Combination therapy with an antitumor alkaloid |
| 09/18/2013 | EP2637661A1 Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| 09/18/2013 | EP2637653A1 Compositions comprising wnt inhibitors for treating cancer |
| 09/18/2013 | EP2637651A1 Composition for treating phonatory and olfactory apparatus disorders |
| 09/18/2013 | CN1697655B Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 09/18/2013 | CN1694959B Non-sequence complementary antiviral oligonucleotides |
| 09/18/2013 | CN103308673A A method for predicting the risk of getting a cardiovascular event in a female subject |
| 09/18/2013 | CN103305567A Bacillus calmette-guerin compound polysaccharide, and preparation method and use thereof |
| 09/18/2013 | CN103304802A Acid-sensing amphipathic segmented copolymer as well as preparation method and application thereof |
| 09/18/2013 | CN103301472A Amphiphilic polysaccharide-anti-tumor medicament conjugate capable of releasing medicines specifically at lesion site of living body, as well as preparation method and application of medicinal composition of amphiphilic polysaccharide-anti-tumor medicament conjugate |
| 09/18/2013 | CN103301465A Preparation and applications of near-infrared light drug controlled release system taking silver/oxidized graphene composite nanoparticle as carrier |
| 09/18/2013 | CN103301464A 药物组合物 The pharmaceutical composition of |
| 09/18/2013 | CN103301463A Compound composition containing plumbago zeylanica for treating livestock and poultry escherichia coli infection diseases |
| 09/18/2013 | CN103301462A Component and method for treating virus disease |
| 09/18/2013 | CN103301461A Long-acting injectable preparation, preparation method and application thereof |
| 09/18/2013 | CN103301441A Medicine for relieving side effect of normal tissue damage caused by chemotherapy |
| 09/18/2013 | CN103301070A Formulations for a tight junction effector |
| 09/18/2013 | CN102618542B MiRNA (microminiature ribonucleic acid) capable of regulating and controlling expression of HLA-G (human leukocyte antigen-G) and application of miRAN |
| 09/18/2013 | CN102357141B Application of Chinese herbal medicine bitter orange extract to preparation of medicament for losing weight and reducing fat or medicament with lipase activity inhabiting function |
| 09/18/2013 | CN102357126B Application of Chinese herbal medicine caulis polygoni multiflori extract in preparing weight-losing and lipid-lowering medicaments or in preparing medicaments with lipase activity inhibition effect |
| 09/18/2013 | CN102145163B Use of CNTF (ciliary neurotrophic factor) receptor activators for the treatment of obesity |
| 09/18/2013 | CN102018672B Freeze-dried liposome composition of water-soluble medicament and preparation method thereof |
| 09/18/2013 | CN101829120B Composition for treatment of external secretion disorders |
| 09/18/2013 | CN101269212B Gargle capable of being swallowed |
| 09/17/2013 | US8536228 Transdermal compositions |
| 09/17/2013 | US8536216 Compositions based on aminoacids |
| 09/17/2013 | US8536156 Contraception process and administration form for the same |
| 09/17/2013 | US8536149 TRPM-2 antisense therapy |
| 09/17/2013 | US8536145 Introducing genetic material topically or by lavage into mucosal tissue cells of an individual, including rectal, vaginal, urethral, sublingual and buccal; used to deliver genetic material that encodes protein targets for immunization against pathogen infection, hyperproliferative or autoimmune diseases |
| 09/17/2013 | US8535899 Assay for identifying a modulator of HIF hydroxylase |
| 09/17/2013 | US8535728 Colloidal silver composition having antimicrobial properties |
| 09/17/2013 | US8535718 Dosage forms of bisphosphonates |
| 09/17/2013 | US8535712 Radiation sensitive liposomes |
| 09/17/2013 | US8535690 Tumor specific animal proteins |
| 09/12/2013 | WO2013134349A1 Delivery systems for enhancing drug efficacy |
| 09/12/2013 | WO2013133351A1 Novel fgfr3 fusion product |
| 09/12/2013 | WO2013132526A1 Use of sphingosine-1 -phosphate receptors modulators for improving vaccine immunization |
| 09/12/2013 | WO2013132444A1 Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria |
| 09/12/2013 | WO2013132044A1 Combination therapy of antibodies against human csf-1r and uses thereof |
| 09/12/2013 | WO2013131927A1 Combining dna-damaging agents and modulators of actin polymerization for the treatment of cancer |
| 09/12/2013 | WO2013131879A1 New application for pasireotide |
| 09/12/2013 | WO2013131496A1 Component and method for treating viral disease |
| 09/12/2013 | WO2013064913A3 Method for treating type i and type ii diabetes |
| 09/12/2013 | US20130239234 Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain |
| 09/12/2013 | US20130237596 Uses of 15-benzylidene-14-deoxy-11,12-didehydroandrographolide Derivatives in the Preparation of Antineoplastic Drugs |
| 09/12/2013 | US20130237584 CANCER THERAPY USING Bcl-XL-SPECIFIC siNA |
| 09/12/2013 | US20130237580 Peptidomimetic compounds as immunomodulators |
| 09/12/2013 | US20130237573 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS |
| 09/12/2013 | US20130237570 Formulation and Use and Manufacture Thereof |
| 09/12/2013 | US20130237569 Modulators of atp-binding cassette transporters |
| 09/12/2013 | US20130237568 Modulators of atp-binding cassette transporters |
| 09/12/2013 | US20130237551 Substituted 5-fluoro-1H-pyrazolopyridines and their use |
| 09/12/2013 | US20130237550 Arylvinylazacycloalkane compounds for constipation |
| 09/12/2013 | US20130237539 Compounds and Compositions for Treating Cancer |
| 09/12/2013 | US20130237535 Fatty acid synthase inhibitors |
| 09/12/2013 | US20130237532 Indole and indazole compounds as an inhibitor of cellular necrosis |